- Home
- HQL vs BBNX Comparison
HQL vs BBNX Comparison
Compare HQL & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HQL | BBNX |
|---|---|---|
| Founded | 1992 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 585.4M | 493.1M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | HQL | BBNX |
|---|---|---|
| Price | $21.23 | $17.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $23.80 |
| AVG Volume (30 Days) | 159.8K | ★ 1.3M |
| Earning Date | 01-01-0001 | 04-21-2026 |
| Dividend Yield | ★ 11.56% | N/A |
| EPS Growth | N/A | ★ 78.95 |
| EPS | ★ 0.79 | N/A |
| Revenue | N/A | ★ $100,251,000.00 |
| Revenue This Year | N/A | $34.90 |
| Revenue Next Year | N/A | $34.63 |
| P/E Ratio | $26.89 | ★ N/A |
| Revenue Growth | N/A | ★ 53.94 |
| 52 Week Low | $13.57 | $8.80 |
| 52 Week High | $21.32 | $32.71 |
Technical Indicators
Market Signals| Indicator | HQL | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 72.46 | 60.44 |
| Support Level | $16.51 | $16.02 |
| Resistance Level | $21.32 | $18.20 |
| Average True Range (ATR) | 0.43 | 1.26 |
| MACD | 0.15 | 0.22 |
| Stochastic Oscillator | 97.64 | 93.69 |
Price Performance
Historical ComparisonAbout HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.
About BBNX Beta Bionics Inc.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.